
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is a well-established Dutch biopharmaceutical company with a successful track record of bringing innovative treatments, such as Vyvgart and Vyvgart Hytrulo, to market for rare autoimmune diseases. With FDA approvals for both products and positive trial results for Empasiprubart, argenx is expected to see strong sales and continue to expand its pipeline for potential treatments in various rare diseases. Although there are risks and uncertainties, the company's solid financials and positive outlook from doctors make it a promising investment option.
Bears say
argenx is experiencing strong market growth due to the approval and commercial success of their lead product, Vyvgart, in the treatment of gMG and CIDP. However, there are concerns about the sustainability of this growth, as the company faces challenges such as potential gross-to-net impacts and potential competition in the future. The success of upcoming pipeline products, such as empasiprubart, will also be crucial in maintaining this growth trajectory.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares